Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence.

Authors :: Gouvea MDPG
Moulaz IR
Gouveia TM
Lança KEM
Lacerda BSP
Thompson BP
Polese J
Lima MD
Ribeiro-Rodrigues R
Mill JG
Valim V
Source :: Revista da Sociedade Brasileira de Medicina Tropical [Rev Soc Bras Med Trop] 2022 Oct 24; Vol. 55, pp. e01062022. Date of Electronic Publication: 2022 Oct 24 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Background: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence.<br />Methods: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N.<br />Results: Four recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms.<br />Conclusions: Undetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.